NOVELIX
NOVELIX PHARMACEUTICALS financials
- Market cap
- ₹112 Cr
Quarterly results
Q2 FY23: revenue down 49.6%, net profit down 142.9% against the same quarter last year.
| Line item | Q3 FY21 | Q4 FY21 | Q1 FY22 | Q2 FY22 | Q3 FY22 | Q4 FY22 | Q1 FY23 | Q2 FY23 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 2 | 3 | 4 | 2 | 1 −49% | 1 −73% | 1 −69% | 1 −50% |
| EBITDA | -0 | -3 | -0 | 0 | -1 −288% | -2 +50% | -0 +18% | -0 −227% |
| Net profit | -0 | -3 | -0 | 0 | -1 −217% | -2 +52% | -0 −12% | -0 −143% |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Performance +84.5% 1Y
1Y: ₹42 on 10 Sept 2025 → ₹77.5. High ₹88.8 (16 Jun 2026), low ₹38.11 (19 Sept 2025).
Financials, as filed
Revenue fell 6.7% a year over 1 year, FY21 to FY22. Operating margin widened to -30.5%.
| Year ending | FY21 | FY22 |
|---|---|---|
| Revenue | ₹9 Cr | ₹9 Cr |
| Operating profit | ₹-4 Cr | ₹-3 Cr |
| Operating margin | -41.5% | -30.5% |
| Interest | ₹0 Cr | ₹0 Cr |
| Depreciation | ₹0 Cr | ₹0 Cr |
| Net profit | ₹-4 Cr | ₹-2 Cr |
| Net margin | -40.7% | -23.6% |
| Cash from operations | ₹2 Cr | ₹2 Cr |
| Free cash flow | ₹2 Cr | ₹-0 Cr |
| ROCE | -38.2% | -25.7% |
How to read this
From the company's own filings. Margins are computed from the filed sums; a year with an incomplete quarter is left blank rather than estimated.
Balance sheet
| Year ending | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 |
|---|---|---|---|---|---|---|
| Equity capital | ₹8 Cr | ₹8 Cr | ₹8 Cr | ₹8 Cr | ₹8 Cr | ₹8 Cr |
| Reserves | ₹3 Cr | ₹3 Cr | ₹3 Cr | ₹3 Cr | ₹-1 Cr | ₹-1 Cr |
| Borrowings | ₹1 Cr | ₹1 Cr | ₹1 Cr | ₹1 Cr | ₹0 Cr | ₹1 Cr |
| Other liabilities | ₹1 Cr | ₹1 Cr | ₹1 Cr | ₹2 Cr | ₹3 Cr | ₹0 Cr |
| Total liabilities | ₹14 Cr | ₹14 Cr | ₹13 Cr | ₹14 Cr | ₹10 Cr | ₹8 Cr |
| Fixed assets | ₹2 Cr | ₹2 Cr | ₹2 Cr | ₹2 Cr | ₹2 Cr | ₹2 Cr |
| Capital work in progress | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr |
| Investments | ₹0 Cr | ₹1 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr |
| Other assets | ₹11 Cr | ₹11 Cr | ₹11 Cr | ₹12 Cr | ₹8 Cr | ₹6 Cr |
| Total assets | ₹14 Cr | ₹14 Cr | ₹13 Cr | ₹14 Cr | ₹10 Cr | ₹8 Cr |
How to read this
As filed each year. A line the company does not report — deposits for a non-lender, for instance — is left out rather than shown as a row of dashes.
Who owns it
As disclosed at Jul 2026
Since Jun 2025, the public trimmed −1.56 pp while promoters added +1.54 pp. The shareholder count grew 30% to 3,127.
- Promoters
- 54.3%
- Public
- 45.7%
Since Jun 2025
- Public −1.56 pp
- Promoters +1.54 pp
How it drifted, 12 quarters
Over this window promoters fell from 66.9% to 54.3% — −12.6 pp.
Ownership split by quarter, oldest first. Dec '23: Promoters 66.9%, Public 33.1%.Mar '24: Promoters 66.9%, Public 33.1%.Jun '24: Promoters 66.5%, Public 33.5%.Sep '24: Promoters 66.6%, Public 33.4%.Dec '24: Promoters 66.6%, Public 33.5%.Mar '25: Promoters 66.6%, Public 33.4%.Jun '25: Promoters 52.8%, Public 47.3%.Sep '25: Promoters 53.3%, Public 46.7%.Dec '25: Promoters 52.0%, Public 48.0%.Mar '26: Promoters 49.4%, Public 50.6%.Jun '26: Promoters 50.6%, Public 49.4%.Jul '26: Promoters 54.3%, Public 45.7%.
Who bought this quarter
since Jun 2026
Disclosed holders that added to a position or appeared on the register for the first time, biggest addition first.
- Srinidhi Fine-Chemicals Llp +2.06 pp 35.13% held
- Vupparapalli Chandrasekhar Reddy +1.29 pp 10.21% held
- Narhari Belide +0.86 pp 4.21% held
- Neha Gattu +0.35 pp 0.35% held
The same filing shows 8 holders trimming and 2 off the list — both are in the register beside this.
Who is on the register
Named in the Jul 2026 filing
Every holder of NOVELIX PHARMACEUTICALS LIMITED above SEBI's 1% disclosure line, and what changed since Jun 2026.
| Holder | Stake | Change |
|---|---|---|
| Srinidhi Fine-Chemicals Llp | 35.13% | +2.06 pp |
| Vupparapalli Chandrasekhar Reddy | 10.21% | +1.29 pp |
| Mallela Venkatramna Reddy | 6.43% | −1.23 pp |
| Narhari Belide | 4.21% | +0.86 pp |
| Sesha Sai Nikhil Chintalapati | 3.40% | −0.65 pp |
| Srinivasrao Swetha Kanakapur | 3.05% | −0.58 pp |
| Vupparapalli Pavani | 2.55% | −0.48 pp |
| Panchagnula Venkata Lakshmi Narayana Sankara Vara Prasad | 2.20% | −0.42 pp |
| Palakurthi Rakesh | 2.02% | −0.38 pp |
| Gattu Gnana Prakash | 1.40% | −0.27 pp |
| Arati Gattu | 0.35% | −0.07 pp |
| Neha Gattu | 0.35% | +0.35 pp |
A holder disappearing from this list has fallen below the 1% line — it is not necessarily a sale. Percentages are of total shares, as disclosed in the company's own filing. Who was buying across the market this quarter.
Learn to analyse NOVELIX PHARMACEUTICALS LIMITED
Guides on how to read this kind of business and the numbers that matter.